Gregor Diagnostics is developing a suite of semen-based genomic classifier tests to enhance prostate cancer screening and monitoring, providing high sensitivity and specificity while minimizing the need for invasive biopsies. The technology addresses the limitations of current diagnostics, which often lead to overdiagnosis and unnecessary treatments in a significant number of patients.
Funding
$14.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current prostate cancer diagnostics often lack the specificity needed to avoid overdiagnosis and overtreatment, leading to unnecessary invasive biopsies for many men. Existing liquid biopsy tests based on blood and urine samples do not provide sufficient biomarker diversity to accurately assess cancer status.
Solution
Gregor Diagnostics is developing a suite of semen-based genomic classifier tests designed to enhance prostate cancer screening and monitoring. By utilizing semen, a fluid rich in prostate-specific biomarkers, Gregor aims to provide high sensitivity and specificity, minimizing the need for invasive biopsies. Their tests are designed to offer a more accurate and less invasive approach to prostate cancer diagnosis and monitoring, with a focus on bringing sample collection into the patient's home for a more convenient experience. The company's strategy is to develop non-invasive tests that will significantly reduce the number of unnecessary biopsies, saving patients from the discomfort and indignity of these procedures.
Target Audience
The primary audience includes physicians and patients navigating prostate cancer care, particularly those seeking less invasive and more accurate diagnostic and monitoring tools.
Features
- Reflex 1+: A genomic classifier test designed to detect cancer in men prior to biopsy.
- Reflex 2+: A genomic classifier test to differentiate between benign and Grade Group 1 cancers from Grade Group 2+ cancers, providing physicians and patients indicated for biopsy a more traditional option.
- Active Surveillance: A genomic classifier test to regularly monitor patients with prostate cancer currently on active surveillance.
- Non-invasive sample collection that can be done from the patient's home.